End-of-day quote
Korea S.E.
06:00:00 2024-05-27 pm EDT
|
5-day change
|
1st Jan Change
|
180,900
KRW
|
+0.72%
|
|
-3.26%
|
-10.22%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
24,175,552
|
48,989,351
|
27,592,583
|
23,000,359
|
27,970,378
|
37,228,137
|
-
|
-
|
Enterprise Value (EV)
2 |
24,047
|
49,090
|
27,117
|
23,236
|
29,280
|
37,875
|
36,994
|
35,893
|
P/E ratio
|
77.7
x
|
94.4
x
|
47.2
x
|
41.6
x
|
53.7
x
|
71.1
x
|
34
x
|
24.1
x
|
Yield
|
-
|
-
|
0.38%
|
-
|
0.25%
|
0.24%
|
0.26%
|
0.31%
|
Capitalization / Revenue
|
21.4
x
|
26.5
x
|
14.6
x
|
10.1
x
|
12.9
x
|
10.6
x
|
8.88
x
|
7.51
x
|
EV / Revenue
|
21.3
x
|
26.5
x
|
14.3
x
|
10.2
x
|
13.5
x
|
10.8
x
|
8.83
x
|
7.24
x
|
EV / EBITDA
|
44.8
x
|
55.1
x
|
27.9
x
|
26.6
x
|
32.6
x
|
38.5
x
|
22.4
x
|
16.2
x
|
EV / FCF
|
63.3
x
|
186
x
|
46
x
|
-211
x
|
89.5
x
|
72.3
x
|
38.4
x
|
32
x
|
FCF Yield
|
1.58%
|
0.54%
|
2.17%
|
-0.47%
|
1.12%
|
1.38%
|
2.6%
|
3.12%
|
Price to Book
|
8.27
x
|
14.4
x
|
6.87
x
|
5.34
x
|
2.46
x
|
2.24
x
|
2.25
x
|
1.96
x
|
Nbr of stocks (in thousands)
|
144,521
|
144,757
|
144,931
|
143,304
|
138,811
|
205,794
|
-
|
-
|
Reference price
3 |
167,280
|
338,424
|
190,385
|
160,500
|
201,500
|
180,900
|
180,900
|
180,900
|
Announcement Date
|
2/19/20
|
2/22/21
|
2/16/22
|
3/3/23
|
2/29/24
|
-
|
-
|
-
|
1KRW in Million2KRW in Billions3KRW Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,128
|
1,849
|
1,891
|
2,284
|
2,176
|
3,500
|
4,192
|
4,959
|
EBITDA
1 |
537.3
|
891.4
|
972.1
|
873.6
|
897.2
|
984.3
|
1,653
|
2,217
|
EBIT
1 |
378.1
|
712.1
|
753.9
|
647.2
|
651.5
|
692
|
1,518
|
2,137
|
Operating Margin
|
33.5%
|
38.51%
|
39.87%
|
28.34%
|
29.93%
|
19.77%
|
36.21%
|
43.1%
|
Earnings before Tax (EBT)
1 |
378.6
|
650.7
|
746.9
|
626.2
|
671.1
|
691.2
|
1,518
|
2,045
|
Net income
1 |
297.6
|
511.3
|
575.1
|
533.2
|
535.6
|
544.1
|
1,132
|
1,594
|
Net margin
|
26.37%
|
27.65%
|
30.42%
|
23.34%
|
24.61%
|
15.55%
|
26.99%
|
32.15%
|
EPS
2 |
2,153
|
3,586
|
4,031
|
3,855
|
3,753
|
2,543
|
5,314
|
7,497
|
Free Cash Flow
3 |
379,716
|
263,739
|
589,594
|
-110,305
|
327,112
|
524,167
|
963,000
|
1,121,000
|
FCF margin
|
33,649.04%
|
14,262.95%
|
31,181.9%
|
-4,829.54%
|
15,029.76%
|
14,975.83%
|
22,973.27%
|
22,606.07%
|
FCF Conversion (EBITDA)
|
70,673.9%
|
29,586.45%
|
60,648.72%
|
-
|
36,460.8%
|
53,251.03%
|
58,262.29%
|
50,565.96%
|
FCF Conversion (Net income)
|
127,593.57%
|
51,582.76%
|
102,521.45%
|
-
|
61,068.54%
|
96,334.49%
|
85,108.26%
|
70,315.2%
|
Dividend per Share
2 |
-
|
-
|
721.2
|
-
|
500.0
|
439.3
|
476.8
|
555.8
|
Announcement Date
|
2/19/20
|
2/22/21
|
2/16/22
|
3/3/23
|
2/29/24
|
-
|
-
|
-
|
1KRW in Billions2KRW3KRW in Million Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
601.1
|
550.6
|
596.1
|
645.6
|
510.6
|
597.5
|
524
|
672.3
|
382.6
|
737
|
792.7
|
921.3
|
1,050
|
975.3
|
1,063
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
147
|
200
|
-
|
-
|
445
|
489
|
EBIT
1 |
219
|
142.3
|
199
|
213.8
|
100.6
|
182.4
|
183
|
267.6
|
18.42
|
15.44
|
94.57
|
231.8
|
341.2
|
320.8
|
374.4
|
Operating Margin
|
36.43%
|
25.84%
|
33.38%
|
33.11%
|
19.71%
|
30.52%
|
34.92%
|
39.81%
|
4.82%
|
2.09%
|
11.93%
|
25.15%
|
32.51%
|
32.89%
|
35.21%
|
Earnings before Tax (EBT)
|
145.2
|
-
|
226.8
|
217.3
|
48.49
|
208.2
|
189.7
|
282.9
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
120.5
|
118.5
|
183.4
|
166.7
|
64.53
|
166.9
|
147.5
|
221.8
|
1.054
|
22.44
|
87.17
|
219.8
|
277.7
|
296
|
331
|
Net margin
|
20.04%
|
21.53%
|
30.77%
|
25.82%
|
12.64%
|
27.93%
|
28.15%
|
33%
|
0.28%
|
3.04%
|
11%
|
23.86%
|
26.46%
|
30.35%
|
31.13%
|
EPS
2 |
-
|
-
|
-
|
1,162
|
470.0
|
1,155
|
1,034
|
1,561
|
-
|
-
|
494.3
|
954.4
|
1,330
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
500.0
|
-
|
-
|
-
|
200.0
|
-
|
-
|
Announcement Date
|
2/16/22
|
5/12/22
|
8/5/22
|
11/9/22
|
3/3/23
|
5/8/23
|
8/14/23
|
11/7/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
100
|
-
|
236
|
1,310
|
647
|
-
|
-
|
Net Cash position
1 |
128
|
-
|
476
|
-
|
-
|
-
|
234
|
1,335
|
Leverage (Debt/EBITDA)
|
-
|
0.1126
x
|
-
|
0.2696
x
|
1.46
x
|
0.6571
x
|
-
|
-
|
Free Cash Flow
2 |
379,716
|
263,739
|
589,594
|
-110,305
|
327,112
|
524,167
|
963,000
|
1,121,000
|
ROE (net income / shareholders' equity)
|
11.2%
|
16.7%
|
16.5%
|
12.9%
|
5.07%
|
3.15%
|
7.77%
|
8.33%
|
ROA (Net income/ Total Assets)
|
8.02%
|
11.6%
|
10.7%
|
9.22%
|
4.31%
|
2.89%
|
5.51%
|
7.03%
|
Assets
1 |
3,713
|
4,402
|
5,372
|
5,783
|
12,421
|
18,855
|
20,519
|
22,667
|
Book Value Per Share
3 |
20,218
|
23,501
|
27,732
|
30,040
|
81,950
|
80,838
|
80,375
|
92,171
|
Cash Flow per Share
3 |
3,430
|
2,460
|
6,417
|
6.250
|
3,764
|
3,945
|
7,788
|
10,103
|
Capex
1 |
94.3
|
87
|
63.4
|
111
|
210
|
107
|
152
|
152
|
Capex / Sales
|
8.35%
|
4.71%
|
3.35%
|
4.87%
|
9.65%
|
3.04%
|
3.63%
|
3.07%
|
Announcement Date
|
2/19/20
|
2/22/21
|
2/16/22
|
3/3/23
|
2/29/24
|
-
|
-
|
-
|
1KRW in Billions2KRW in Million3KRW Last Close Price
180,900
KRW Average target price
233,647
KRW Spread / Average Target +29.16% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.22% | 27.17B | | +54.05% | 63.85B | | -2.02% | 41.83B | | +40.01% | 40.47B | | +13.42% | 26.52B | | -21.60% | 18.69B | | +2.89% | 12.73B | | +22.40% | 12.11B | | +27.49% | 12.07B | | -9.26% | 11.19B |
Other Biotechnology & Medical Research
|